Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2010 Jan;17(1):14-7.
doi: 10.1245/s10434-009-0766-0. Epub 2009 Oct 20.

Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance

Dimitrios H Roukos
Editorial

Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance

Dimitrios H Roukos. Ann Surg Oncol. 2010 Jan.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
a Ligand binding and subsequent Erbb dimer formation initiates signaling through a complex array of intracellular pathways that initiate and control a range of cellular processes. Dimer formation results in the cross-phosphorylation of the dimer partners, creating docking sites that allow the recruitment of downstream signaling components and the formation of signaling complexes. Two key signaling pathways activated by the Erbb family dimers are the MAPK pathway, which stimulates proliferation, and the PI3K–Akt pathway, which promotes tumor cell survival (see the figure). Only signaling through these two pathways and some of the known outcomes are shown here for simplicity. b The antibody trastuzumab binds directly to domain IV of the extracellular region of ERBB2, suppressing ERBB2 signaling activity, preventing cleavage of the extracellular domain, and marking tumor cells that overexpress ERBB2 for further immunological attack through antibody-dependent cell-mediated cytotoxicity. GSK3β, glycogen synthase kinase 3β; NF-κB, nuclear factor-κB; PDK1, pyruvate dehydrogenase kinase 1; PIP2, phosphatidylinositol biphosphate; PIP3, phosphatidylinositol triphosphate
See this image and copyright information in PMC

References

    1. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005;353(16):1652–1654. doi: 10.1056/NEJMp058197. - DOI - PubMed
    1. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004;4(5):361–370. doi: 10.1038/nrc1360. - DOI - PubMed
    1. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9(7):463–475. doi: 10.1038/nrc2656. - DOI - PubMed
    1. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523–1529. doi: 10.1093/annonc/mdn169. - DOI - PubMed
    1. Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC) J Clin Oncol. 2009;27:18s. doi: 10.1200/JCO.2009.22.4626. - DOI

Publication types

MeSH terms